Abstract
Show me the genes – I will tell you who/how to treat!
Highlights
The recently published study from the National Surgical Adjuvant Breast and Bowel Project (NSABP) group lead by Paik [1], in collaboration with Genomic Health Inc., represents a landmark trial in this field
Using quantitative RT-PCR, these researchers developed a recurrence score based on 21 genes that appears to predict accurately the likelihood of distant recurrence in tamoxifen-treated patients with node-negative, oestrogen receptor (ER)-positive breast cancer
Cutoff points were chosen based on the results of NSABP trial B-20, and allowed for the classification of patients into three risk categories: low risk, intermediate risk, and high risk
Summary
The recently published study from the National Surgical Adjuvant Breast and Bowel Project (NSABP) group lead by Paik [1], in collaboration with Genomic Health Inc., represents a landmark trial in this field. Using quantitative RT-PCR, these researchers developed a recurrence score based on 21 genes that appears to predict accurately the likelihood of distant recurrence in tamoxifen-treated patients with node-negative, oestrogen receptor (ER)-positive breast cancer.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
